Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer
暂无分享,去创建一个
Robert Brown | A. Richardson | G. Cancel-Tassin | O. Cussenot | W. Isaacs | E. Schaeffer | E. Antonarakis | J. Lanchbury | T. Lotan | K. Timms | D. Salles | S. Murali | Harsimar B. Kaur | Daniela C. Salles | G. Cancel‐Tassin
[1] E. Antonarakis,et al. BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike? , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] C. Higano,et al. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] B. Trock,et al. Genomic and Clinicopathologic Characterization of ATM-deficient Prostate Cancer , 2020, Clinical Cancer Research.
[4] W. Foulkes,et al. Etiologic Index - A Case-Only Measure of BRCA1/2-Associated Cancer Risk. , 2020, The New England journal of medicine.
[5] E. Antonarakis,et al. PARP inhibitors in prostate cancer: time to narrow patient selection? , 2020, Expert review of anticancer therapy.
[6] F. Saad,et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.
[7] E. Antonarakis,et al. Therapeutic targeting of the DNA damage response in prostate cancer. , 2020, Current opinion in oncology.
[8] F. Feng,et al. Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study , 2020, Clinical Cancer Research.
[9] F. Saad,et al. TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA). , 2020 .
[10] Z. Szallasi,et al. Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations , 2020, Clinical Cancer Research.
[11] Z. Szallasi,et al. Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents , 2019, Genome Biology.
[12] E. Antonarakis,et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. , 2019, European urology.
[13] A. Chinnaiyan,et al. Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer , 2019, Clinical Cancer Research.
[14] W. Isaacs,et al. Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy. , 2019, JCO precision oncology.
[15] N. Socci,et al. Tumour lineage shapes BRCA-mediated phenotypes , 2019, Nature.
[16] E. Antonarakis,et al. Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analysis. , 2019, Journal of Clinical Oncology.
[17] J. Gregg,et al. Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors , 2019, JCO precision oncology.
[18] R. Nussbaum,et al. Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines , 2019, JAMA oncology.
[19] H. Scher,et al. Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD. , 2019, Journal of Clinical Oncology.
[20] J. Reid,et al. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer , 2018, British Journal of Cancer.
[21] Rui Bi,et al. The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. , 2018, Journal of the National Cancer Institute.
[22] Joshua M. Stuart,et al. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer , 2018, Cell.
[23] Robert Brown,et al. Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy , 2018, Molecular Cancer Research.
[24] G. Cancel-Tassin,et al. Comparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy , 2018, World Journal of Urology.
[25] Bruce Montgomery,et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Z. Szallasi,et al. The association between germline BRCA2 variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancer , 2017, Cancer.
[27] E. Lander,et al. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer , 2017, Nature Genetics.
[28] J. Eshleman,et al. MSH2 Loss in Primary Prostate Cancer , 2017, Clinical Cancer Research.
[29] K. Cooney,et al. Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death , 2017 .
[30] E. Kohn,et al. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization , 2017, Clinical Cancer Research.
[31] F. d’Adda di Fagagna,et al. A novel single‐cell method provides direct evidence of persistent DNA damage in senescent cells and aged mammalian tissues , 2017, Aging cell.
[32] Marilyn M. Li,et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.
[33] Ahmet Zehir,et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. , 2016, The New England journal of medicine.
[34] Z. Szallasi,et al. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer , 2016, Clinical Cancer Research.
[35] Steven J. M. Jones,et al. The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.
[36] Wei Yuan,et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.
[37] J. Hicks,et al. PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas , 2015, The Prostate.
[38] Alexander Gutin,et al. Association of BRCA1/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes , 2014, Breast Cancer Research.
[39] Igor Jurisica,et al. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. , 2014, The Lancet. Oncology.
[40] F. Couch,et al. Functional Assays for Analysis of Variants of Uncertain Significance in BRCA2 , 2014, Human mutation.
[41] Benjamin J. Raphael,et al. Integrated Analysis of Germline and Somatic Variants in Ovarian Cancer , 2014, Nature Communications.
[42] J. Hicks,et al. Immunohistochemistry for ERG Expression as a Surrogate for TMPRSS2-ERG Fusion Detection in Prostatic Adenocarcinomas , 2011, The American journal of surgical pathology.
[43] Wei Yan,et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. , 2011, Cancer cell.
[44] T. Halazonetis,et al. Genomic instability — an evolving hallmark of cancer , 2010, Nature Reviews Molecular Cell Biology.
[45] L. Staudt,et al. Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[46] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[47] A. Pettitt,et al. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. , 2001, Blood.